Following the opinion updating the data on hydroxychloroquine, remdesivir and tocilizumab, the Haut Conseil de la santé publique updates the recommendations for other therapies in the management of Covid-19, after a review and analysis of the literature and international guidelines.

Following this analysis, the HCSP’s recommendations for the treatment of Covid-19 are as follows:

• The implementation of a supportive treatment adapted to the patient’s condition in all situations, this treatment being the reference. The recommendations relating to corticosteroid therapy, anticoagulant treatment, analgesics and antibiotics remain unchanged from previous HCSP opinions.
• Immunotherapy: recommendations on the use of convalescent plasma remain unchanged, interferons and polyvalent immunoglobulins are not recommended outside of randomised clinical trials, and certain monoclonal antibodies can only be prescribed on a discretionary basis to a very limited population of hospitalised patients.
• Mesenchymal cells and repositioned drugs (enzyme conversion inhibitors, ivermectin, statins, etc.) are not recommended outside randomised clinical trials, and protease inhibitors should not be used.
• Corticosteroids are indicated for oxygen-deficient patients in accordance with previous HCSP opinions.
• Vitamins (C or D) and zinc are not indicated, unless supplementation is required.